Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
Enrico Derenzini(University of Milan), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Stefano Pileri(European Institute of Oncology), Clelia Tiziana Storlazzi(University of Bari Aldo Moro), Ilaria Iacobucci(St. Jude Children's Research Hospital), Alberto L’Abbate(Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies), Beatrice Casadei(Istituto di Ematologia di Bologna), Giovanni Martinelli(University of Bologna), Enrica Imbrogno(University of Bologna), Claudio Agostinelli, Anna Ferrari(University of Bologna)
Cited by 6
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k